High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN)

  • STATUS
    Recruiting
  • End date
    Nov 28, 2032
  • participants needed
    800
  • sponsor
    Gustave Roussy, Cancer Campus, Grand Paris
Updated on 19 February 2024
cancer
fever
bone disease
heart disease
renal function
carboplatin
bone lesions
x-rays
heart failure
dyspnea
ejection fraction
etoposide
chromosome abnormality
induction chemotherapy
primary tumor
oxygen saturation
phenytoin
myocardial infarction
arrhythmia
obstruction
infarct
oximetry
renal function tests
neuropathy
chest x-ray
hearing impairment
yellow fever
bone marrow procedure
renal function test
residual tumor
kidney function test
localized disease
fdg pet
st. john's wort
avid
shortening fraction
residual disease
peripheral neuropathy
inflammatory bowel disease
hyperhydration
fdg-pet
pulse oximetry
chromosomal abnormalities
dyspnea at rest
high-risk neuroblastoma
bone lesion
mycn
bacterial vaccines
bowel obstruction
mibg
intestinal obstruction
consolidation chemotherapies
bone marrow disease
yellow fever vaccine
prophylactic
neuroblastoma
renal toxicity
acute infarct
blood bilirubin
localized neuroblastoma
hypericum perforatum
numerical chromosomal alterations
charcot-marie-tooth syndrome
infarct, acute

Summary

This is an international multicenter, open-label, randomized phase III trial including three sequential randomizations to assess efficacy of induction and consolidation chemotherapies and radiotherapy for patients with high-risk neuroblastoma.

Description

This is an international multicenter, open-label, randomized phase III trial including three sequential randomizations to assess efficacy of induction and consolidation chemotherapies and radiotherapy for patients with high-risk neuroblastoma.

The first randomization (R-I) will compare the efficacy of two induction chemotherapies (RAPID COJEC and GPOH regimens) in a phase III setting. The primary endpoint will be the 3-year EFS from date of randomization . The R-I randomization will be stratified on age, stage, MYCN status and countries.

The second randomization (R-HDC) will compare the efficacy of single HDC with Bu-Mel versus tandem HDC with Thiotepa followed by Bu-Mel. The primary endpoint is 3-year EFS calculated from the date of the R-HDC randomization. The R-HDC randomization will be stratified on the age, stage, MYCN status, induction chemotherapy regimen, response to induction phase and countries.

The impact of local treatment in this phase III setting will be assessed, according to the presence or not of a macroscopic residual disease after surgery and HDC.

In case of macroscopic residual disease, 21.6 Gy radiotherapy to the preoperative tumor bed will be randomized (R-RTx) versus the same treatment plus a sequential boost of additional 14.4 Gy to the residual tumor. The primary endpoint of R-RTx is 3-year EFS from the date of the R-RTx randomization. The R-RTx randomization will be stratified on age, stage, MYCN status, induction chemotherapy regimen, HDC regimen and countries.

In case of no macroscopic residual disease, 21.6 Gy radiotherapy will be delivered to the preoperative tumor bed.

Details
Condition High-Risk Neuroblastoma
Age 21 years and younger
Treatment Cyclophosphamide, Carboplatin, Vincristine, Thiotepa, Etoposide, Vindesine, Dacarbazine, Ifosfamide, Doxorubicin, Busulfan, Melphalan, Radiotherapy, Dinutuximab Beta, Cisplatin
Clinical Study IdentifierNCT04221035
SponsorGustave Roussy, Cancer Campus, Grand Paris
Last Modified on19 February 2024

Eligibility

Yes No Not Sure

Inclusion Criteria

Urinary outflow obstruction
severe arrhythmia, heart failure, previous cardiac infarct, acute inflammatory heart disease
severe peripheral neuropathy
demyelinating form of Charcot-Marie-Tooth syndrome
hearing impairment
Concurrent prophylactic use of phenytoin
cardiorespiratory disease that contraindicates hyperhydration
Non-inclusion criteria common to all randomizations (R-I, R-HDC and R-RTx)
Any negative answer concerning the inclusion criteria of R-I or R-HDC or R-RTx will render the patient ineligible for the corresponding therapy phase randomization. However, these patients may remain on study and be considered to receive standard treatment of the respective therapy phase, and may be potentially eligible for subsequent randomizations
Liver function: Alanine aminotransferase (ALT) > 3.0 x ULN and blood bilirubin > 1.5 x ULN (toxicity grade 2). In case of toxicity grade 2, call national principal investigator study coordinator to discuss the feasibility
Renal function: Creatinine clearance and/or GFR < 60 ml/min/1.73m (toxicity grade 2). If GFR < 60ml/min/1.73m, call national principal investigator to discuss.the feasibility
Dyspnea at rest and/or pulse oximetry <95% in air
Any uncontrolled intercurrent illness or infection that in the investigator opinion would impair study participation
Patient under guardianship or deprived of his liberty by a judicial or administrative decision or incapable of giving his consent
Participating in another clinical study with an IMP while on study treatment
Concomittant use with yellow fever vaccine and with live virus or bacterial vaccines
Patient allergic to peanut or soya
Chronic inflammatory bowel disease and/or bowel obstruction
Pregnant or breastfeeding women
Known hypersensitivity to the active substance or to any of the excipients of study drugs known
Concomitant use with St John's Wort (Hypericum Perforatum)
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.